Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Name
Prof. Frédéric Amant
Title
KU Leuven
Bio
Clinical activity
Frédéric Amant (MD, PhD) received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998 and his subspecialty training in gynecologic oncology in 2000. He is professor at the KU Leuven in Belgium and at the University of Amsterdam (UvA) in the Netherlands, visiting professor at the university of Bergen, Norway, and honorary professor at the university of Pretoria, South Africa. He is specialist at the Netherlands Cancer Institute.
Research activity
Frédéric Amant heads the Gynecologic Oncology research section at the University of Leuven, Belgium and at the Netherlands Cancer Institute.
In 2005 he founded the ESGO taskforce on Cancer in Pregnancy, now the “International Network on Cancer, Infertility and Pregnancy” (INCIP) (www.cancerinpregnancy.org), and chairs this network up till now. Since 2014, INCIP also registers young women who aim to preserve their fertility.
In addition, Frédéric Amant founded Trace, the tumor xenograft platform at the KU Leuven, aiming to bring basic research closer to the clinic. He co-founded ENITEC, the European Network on Individualized Treatment of Endometrial Cancer.
Frédéric Amant (MD, PhD) received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998 and his subspecialty training in gynecologic oncology in 2000. He is professor at the KU Leuven in Belgium and at the University of Amsterdam (UvA) in the Netherlands, visiting professor at the university of Bergen, Norway, and honorary professor at the university of Pretoria, South Africa. He is specialist at the Netherlands Cancer Institute.
Research activity
Frédéric Amant heads the Gynecologic Oncology research section at the University of Leuven, Belgium and at the Netherlands Cancer Institute.
In 2005 he founded the ESGO taskforce on Cancer in Pregnancy, now the “International Network on Cancer, Infertility and Pregnancy” (INCIP) (www.cancerinpregnancy.org), and chairs this network up till now. Since 2014, INCIP also registers young women who aim to preserve their fertility.
In addition, Frédéric Amant founded Trace, the tumor xenograft platform at the KU Leuven, aiming to bring basic research closer to the clinic. He co-founded ENITEC, the European Network on Individualized Treatment of Endometrial Cancer.
